Hill-Rom Holdings Inc. to Post Q2 2017 Earnings of $0.81 Per Share, Northcoast Research Forecasts (HRC)
Hill-Rom Holdings Inc. (NYSE:HRC) – Investment analysts at Northcoast Research dropped their Q2 2017 earnings estimates for Hill-Rom Holdings in a report released on Monday. Northcoast Research analyst D. Keiser now expects that the brokerage will post earnings per share of $0.81 for the quarter, down from their previous forecast of $0.82. Northcoast Research also issued estimates for Hill-Rom Holdings’ Q3 2017 earnings at $0.93 EPS, FY2017 earnings at $3.80 EPS, Q1 2018 earnings at $0.87 EPS, Q2 2018 earnings at $0.91 EPS, Q3 2018 earnings at $1.04 EPS and FY2018 earnings at $4.25 EPS.
Separately, Zacks Investment Research upgraded Hill-Rom Holdings from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research report on Wednesday, September 21st. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $62.20.
Hill-Rom Holdings (NYSE:HRC) traded up 2.20% during trading on Wednesday, reaching $54.73. The company’s stock had a trading volume of 183,033 shares. The stock has a 50-day moving average price of $59.19 and a 200 day moving average price of $54.47. The company has a market cap of $3.66 billion, a PE ratio of 29.42 and a beta of 1.20. Hill-Rom Holdings has a 52-week low of $42.99 and a 52-week high of $63.12.
Hill-Rom Holdings (NYSE:HRC) last posted its earnings results on Thursday, November 3rd. The medical technology company reported $1.18 EPS for the quarter, beating the consensus estimate of $1.13 by $0.05. The firm earned $706 million during the quarter, compared to the consensus estimate of $701.39 million. Hill-Rom Holdings had a return on equity of 18.93% and a net margin of 4.67%. The business’s quarterly revenue was up 23.0% on a year-over-year basis. During the same period last year, the company earned $0.89 earnings per share.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Nordea Investment Management AB raised its stake in Hill-Rom Holdings by 278.3% in the second quarter. Nordea Investment Management AB now owns 12,670 shares of the medical technology company’s stock worth $639,000 after buying an additional 9,321 shares in the last quarter. Foundry Partners LLC purchased a new position in shares of Hill-Rom Holdings during the second quarter valued at approximately $9,209,000. Capstone Asset Management Co. raised its stake in Hill-Rom Holdings by 4.2% in the second quarter. Capstone Asset Management Co. now owns 7,225 shares of the medical technology company’s stock worth $365,000 after buying an additional 290 shares in the last quarter. Fisher Asset Management LLC raised its stake in Hill-Rom Holdings by 0.4% in the second quarter. Fisher Asset Management LLC now owns 1,576,535 shares of the medical technology company’s stock worth $80,466,000 after buying an additional 5,975 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its stake in Hill-Rom Holdings by 3,757.5% in the second quarter. BNP Paribas Arbitrage SA now owns 23,608 shares of the medical technology company’s stock worth $1,191,000 after buying an additional 22,996 shares in the last quarter. Hedge funds and other institutional investors own 83.10% of the company’s stock.
About Hill-Rom Holdings
Hill-Rom Holdings, Inc is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. Its segments include North America, Surgical and Respiratory Care, International and Welch Allyn.
Receive News & Stock Ratings for Hill-Rom Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc. and related stocks with our FREE daily email newsletter.